Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
TG Therapeutics, Inc is a biotechnology business based in the US. TG Therapeutics shares (TGTX) are listed on the NASDAQ and all prices are listed in US Dollars. TG Therapeutics employs 301 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$37.16|
|52-week range||$17.67 - $56.74|
|50-day moving average||$37.98|
|200-day moving average||$42.48|
|Wall St. target price||$72.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.96|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-8.13%|
|3 months (2021-04-30)||-16.89%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
|Gross profit TTM||$152,000|
|Return on assets TTM||-60.06%|
|Return on equity TTM||-143.67%|
|Market capitalisation||$5 billion|
TTM: trailing 12 months
There are currently 11.0 million TG Therapeutics shares held short by investors – that's known as TG Therapeutics's "short interest". This figure is 2.6% up from 10.8 million last month.
There are a few different ways that this level of interest in shorting TG Therapeutics shares can be evaluated.
TG Therapeutics's "short interest ratio" (SIR) is the quantity of TG Therapeutics shares currently shorted divided by the average quantity of TG Therapeutics shares traded daily (recently around 880038.64541833). TG Therapeutics's SIR currently stands at 12.55. In other words for every 100,000 TG Therapeutics shares traded daily on the market, roughly 12550 shares are currently held short.
However TG Therapeutics's short interest can also be evaluated against the total number of TG Therapeutics shares, or, against the total number of tradable TG Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TG Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 TG Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.0921% of the tradable shares (for every 100,000 tradable TG Therapeutics shares, roughly 92 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against TG Therapeutics.
Find out more about how you can short TG Therapeutics stock.
We're not expecting TG Therapeutics to pay a dividend over the next 12 months.
TG Therapeutics's shares were split on a 100:5625 basis on 29 April 2012. So if you had owned 5625 shares the day before before the split, the next day you'd have owned 100 shares. This wouldn't directly have changed the overall worth of your TG Therapeutics shares – just the quantity. However, indirectly, the new 5525% higher share price could have impacted the market appetite for TG Therapeutics shares which in turn could have impacted TG Therapeutics's share price.
Over the last 12 months, TG Therapeutics's shares have ranged in value from as little as $17.67 up to $56.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TG Therapeutics's is 2.1251. This would suggest that TG Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
TG Therapeutics, Inc. , a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7. 1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc. , Jiangsu Hengrui Medicine Co.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.